HARDMAN & CO RESEARCH Hardman & Co Research: Redx Pharma (REDX):ROCK2 inhibitors in chronic kidney disease

Transparency directive : regulatory news

09/11/2018 10:50




Hardman & Co Research


Hardman & Co Research: Redx Pharma (REDX):ROCK2 inhibitors in chronic kidney disease


09-Nov-2018 / 09:50 GMT/BST



Hardman & Co: ROCK2 inhibitors in chronic kidney disease



REDX's new management team is continuing to focus its financial resources on progressing lead candidates in oncology and fibrotic disease into the clinic. An extensive internal review, led by the new CEO Lisa Anson has reinforced the vision of a streamlined pipeline in these two disease areas, with the aim of progressing drug candidates to deliver clinical proof-of-concept. 2019 is expected to be a busy year for REDX, with several major milestones due. Meanwhile, REDX has disclosed, for the first time, the profiles of its ROCK2 inhibitors in in vitro and an in vivo kidney damage model, showing potential best-in-class results. Please click here for the full report:



https://www.hardmanandco.com/research/corporate-research/rock2-inhibitors-in-chronic-kidney-disease/






To contact us:


Hardman & Co

35 New Broad Street

London

EC2M 1NH

www.hardmanandco.com
Follow us on Twitter @HardmanandCo
Contacts:


Dr Martin Hall

Dr Dorothea Hill

Dr Gregoire Pave


+44 20 7194 7622


mh@hardmanandco.com
dmh@hardmanandco.com
gp@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.



About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.



Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.



Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
















Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.





End of Announcement - EQS News Service



743747  09-Nov-2018 



fncls.ssp?fn=show_t_gif&application_id=743747&application_name=news&site_id=symex